The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells

PURPOSE: Proteasome-inhibiting drugs (PI) are gaining importance in hematologic oncology. The proteasome carries three proteolytically active subunits (β1, β2, β5). All established PI (bortezomib and carfilzomib), as well as experimental drugs in the field (dalanzomib, oprozomib, and ixazomib), by d...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Chemother Pharmacol
Main Authors: Kraus, Johannes, Kraus, Marianne, Liu, Nora, Besse, Lenka, Bader, Jürgen, Geurink, Paul P., de Bruin, Gerjan, Kisselev, Alexei F., Overkleeft, Herman, Driessen, Christoph
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2015
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4515249/
https://ncbi.nlm.nih.gov/pubmed/26099967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2801-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items